Freepik.comJust over a year and a half ago, it made headlines: Swiss biotech Numab AG, based in Horgen on Lake Zurich, sold a single antibody to Johnson & Johnson for US$1.25 billion via a spin-out vehicle. No back-loaded milestones, no future contingencies — but cash up front, as one might say, straight into the pocket.
Tag Archive for: Johnson & Johnson
Bayer AGPatent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against the makers of mRNA vaccines – just as the market has cooled and the pandemic feels firmly in the rear-view mirror. Understandable from a financial perspective, perhaps, but still raising questions about the timing.